Fosamax: Higher Risk of Jawbone Death?
After Tooth Extraction, Fosamax Patients Have 4% Risk of Jaw Osteonecrosis
Merck notes in a statement that the Sedghizadeh study contains methodological flaws and that the findings cannot be used to reach "valid scientific conclusions regarding the prevalence of osteonecrosis of the jaw" in patients taking Fosamax.
"Data from randomized, prospective clinical trials are the gold standard and are more reliable than data from studies like the [Sedghizadeh study]," the statement reads. "In controlled clinical trials involving more than 17,000 patients, contributing as much as 10 years' data with [Fosamax], there have been no reports of osteonecrosis of the jaw. This includes approximately 3,000 osteoporosis patients taking [Fosamax] for three to five years and approximately 800 patients taking [Fosamax] for eight to 10 years."
Sedghizadeh and colleagues call for other institutions to go through their own records to establish whether patients on Fosamax and other bisphosphonates have a higher risk of jawbone death after dental procedures.
The Sedghizadeh study appears in the January issue of the Journal of the American Dental Association.